Praxis Precision Medicines to Present at Upcoming December Investor Conferences

Core Insights - Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders related to neuronal excitation-inhibition imbalance [1] - The company will participate in two investor conferences in December 2024, including a fireside chat at the Piper Sandler 36th Annual Healthcare Conference and a panel at the Oppenheimer Movers in Rare Disease Summit [2][3] Company Overview - Praxis is leveraging genetic insights from genetic epilepsies to create therapies for CNS disorders, utilizing its proprietary platforms, Cerebrum™ and Solidus™ [5] - The company has a diversified CNS portfolio with multiple programs targeting movement disorders and epilepsy, featuring four clinical-stage product candidates [5]